Broadly reactive mosaic peptide for influenza vaccine
The invention provides for mosaic influenza virus HA and NA sequences and uses thereof.
1. A vaccine comprising a recombinant influenza virus, the genome of which comprises a nucleotide sequence for an influenza virus HA polypeptide consisting of SEQ ID NO:7 or a nucleotide sequence for an influenza viral HA polypeptide with one amino acid substitution relative to SEQ ID NO:7, or the vaccine comprises an influenza virus HA protein consisting of SEQ ID NO:7 or a protein with one amino acid substitution relative to SEQ ID NO:7, or a combination thereof, which provides cross-clade reactivity.
2. The vaccine of claim 1 , further comprising an adjuvant.
3. The vaccine of claim 1 , further comprising a different virus.
4. The vaccine of claim 1 , further comprising a pharmaceutically acceptable carrier.
5. The vaccine of claim 4 , wherein the carrier is suitable for intranasal or intramuscular administration.
6. The vaccine of claim 1 , which is in freeze-dried form.
7. The vaccine of claim 1 , which is adapted for mucosal, intramuscular or intradermal delivery.
8. The vaccine of claim 1 , wherein the influenza virus polypeptide consists of SEQ NO:7, or the influenza virus protein consists of SEQ ID NO:7.
9. A vaccine comprising a recombinant influenza virus, the genome of which comprises a nucleotide sequence for an influenza virus HA polypeptide consisting of SEQ ID NO:7 or a nucleotide sequence for an influenza viral HA polypeptide with one or two amino acid substitutions relative to SEQ ID NO:7, or the vaccine comprises an influenza virus HA protein consisting of SEQ ID NO:7 or a protein with one or two amino acid substitutions relative to SEQ ID NO:7, or a combination thereof, which provides cross-clade reactivity, wherein the one or two substitutions is/are at position(s) 24-29, 51-54, 111-125, 301-303, 324-339, 351, 364-365, 378-379, 403-439, 451-454, 470-483, 506-534, or 551-555.